GSA Capital Partners LLP Takes $1.23 Million Position in Veracyte, Inc. (NASDAQ:VCYT)

GSA Capital Partners LLP purchased a new position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 41,432 shares of the biotechnology company's stock, valued at approximately $1,228,000. GSA Capital Partners LLP owned 0.05% of Veracyte at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Versant Capital Management Inc grew its position in shares of Veracyte by 1,267.6% during the first quarter. Versant Capital Management Inc now owns 930 shares of the biotechnology company's stock worth $28,000 after buying an additional 862 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Veracyte during the fourth quarter worth about $64,000. Sterling Capital Management LLC grew its position in shares of Veracyte by 810.2% during the fourth quarter. Sterling Capital Management LLC now owns 2,421 shares of the biotechnology company's stock worth $96,000 after buying an additional 2,155 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Veracyte during the fourth quarter worth about $152,000. Finally, Neuberger Berman Group LLC acquired a new position in shares of Veracyte during the fourth quarter worth about $201,000.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on VCYT. UBS Group lowered their price target on Veracyte from $49.00 to $42.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Guggenheim lowered their price target on Veracyte from $45.00 to $37.00 and set a "buy" rating for the company in a report on Wednesday, April 9th. Needham & Company LLC lowered their price target on Veracyte from $51.00 to $41.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Finally, Wall Street Zen raised Veracyte from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Veracyte presently has an average rating of "Moderate Buy" and an average target price of $40.90.

Veracyte Price Performance

Shares of VCYT stock traded up $0.13 during trading hours on Friday, hitting $23.64. The stock had a trading volume of 1,741,593 shares, compared to its average volume of 1,967,193. The firm has a market capitalization of $1.85 billion, a PE ratio of 57.66 and a beta of 1.97. Veracyte, Inc. has a twelve month low of $19.73 and a twelve month high of $47.32. The stock's 50 day moving average is $26.30 and its 200 day moving average is $31.73.

Veracyte Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.